The physical and digital biobank supports the integration of artificial intelligence in acute care diagnostics development.

The tests run on the company's TruVerus benchtop instrument, which provides results from a blood sample in minutes.

Last week, readers were most interested in a story about concerns about BillionToOne's Unity NIPT due to false negative results.

The company said its preliminary revenues for the fourth quarter were at least $21 million, and its full-year 2025 revenues are expected to grow to $77 million.

The firm said it has appointed Abhishek Jain, a veteran of CareDx and Agilent Technologies, to be its next chief financial officer.

For full-year 2025, MDxHealth's preliminary revenues are $109 million, up 21 percent from 90.0 million in 2024. It billed 49,180 tissue-based units, up from 18 percent year over year, and 71,920 ...

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

The funding will support final development, clinical validation, regulatory approval, and commercial launch of an ultra-rapid AST platform.

The next phase of funding will allow the team to launch a clinical trial to test a novel way of making early gastric tumors easier to identify during endoscopy procedures.

NEW YORK – Cardiovascular testing firm Prevencio and Quadrant Health said Thursday that they have entered an agreement to integrate Prevencio's HART CVE and HART CADhs blood tests into Quadrant's ...